AI in Healthcare: From Hype to Pipeline

Introduction

AI in healthcare has progressed from conference-deck aspiration to clinical pipeline reality. The transition is measurable: over 200 AI-discovered or AI-designed drug candidates are now in clinical development, the FDA has authorized more than 1,000 AI/ML-enabled medical devices, and every major pharma company has built or acquired AI capabilities for drug discovery, clinical trial optimization, and manufacturing. At JPM 2026, the narrative shifted decisively: AI is no longer a differentiator that companies trumpet in investor presentations. It is infrastructure that companies are expected to have.

The most commercially significant application of AI in healthcare is drug discovery, where AI platforms can compress target identification and lead optimization timelines from years to months. The landmark proof point is Insilico Medicine's ISM001-055, a drug for idiopathic pulmonary fibrosis that was the first fully AI-discovered compound to report positive Phase 2a clinical data. The entire process, from target identification to clinical candidate nomination, took approximately 18 months versus the traditional 4-5 year timeline.

AI-Native Biotech

A biotechnology company that uses AI/ML as its core platform for drug discovery and development, rather than layering AI onto traditional discovery workflows. Companies like Recursion Pharmaceuticals, Insilico Medicine, Isomorphic Labs (DeepMind), and Exscientia have built proprietary datasets and models that generate novel molecular structures, predict binding affinity, and optimize ADMET (absorption, distribution, metabolism, excretion, toxicity) properties computationally before synthesizing physical compounds. The investment thesis is that AI-native platforms generate more candidates, faster, at lower cost, and with higher probability of clinical success.

Major pharma companies are acquiring AI capabilities rather than building from scratch. Recursion Pharmaceuticals' $688 million merger with Exscientia in 2025 consolidated two leading AI drug discovery platforms. Sanofi committed $1.2 billion to AI drug discovery partnerships. Novartis, Roche, and AstraZeneca have each built internal AI divisions or signed multi-target licensing deals with AI-native biotechs. These partnerships and acquisitions create a growing M&A pipeline for healthcare bankers advising AI drug discovery companies.

The FDA has authorized over 1,000 AI/ML-enabled medical devices, with the pace accelerating: approximately 300 new authorizations in 2025 alone. The vast majority are in radiology (automated image analysis for screening and diagnosis), cardiology (ECG interpretation, arrhythmia detection), and pathology (digital pathology for cancer grading).

For healthcare bankers, the AI diagnostic space presents both M&A advisory and valuation opportunities. Diagnostic AI companies with FDA-cleared algorithms and established clinical adoption are acquisition targets for large device companies (medtech tuck-in strategy) and health IT platforms. The key valuation driver is whether the AI product can achieve reimbursement, since many AI diagnostic algorithms lack dedicated CPT codes and rely on bundled payment or institutional purchasing.

The next article examines the $236 billion patent cliff and why it is driving a biopharma M&A supercycle.